Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:7:135-49.
doi: 10.2147/NDT.S12769. Epub 2011 Mar 17.

Pharmacotherapy for treatment-resistant schizophrenia

Meghan E McIlwain  1 , Jeff Harrison, Amanda J Wheeler, Bruce R Russell
Affiliations

Pharmacotherapy for treatment-resistant schizophrenia

Meghan E McIlwain et al. Neuropsychiatr Dis Treat. 2011.

Abstract

Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine.

Keywords: antipsychotic; clozapine; refractory.

PubMed Disclaimer

References

    1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. - PMC - PubMed
    1. Marder SR. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. J Clin Psychiatry. 2006;67(7):e03. - PubMed
    1. Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A. The Australian national survey of psychotic disorders: Profile of psychosocial disability and its risk factors. Psychol Med. 2002;32(4):639–647. - PubMed
    1. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, et al. Psychotic disorders in urban areas: An overview of the study on low prevalence disorders. Aust N Z J Psychiatry. 2000;34(2):221–236. - PubMed
    1. Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, et al. The personal impact of schizophrenia in europe. Schizophr Res. 2004;69(2–3):125–132. - PubMed